Literature DB >> 4050335

Spread and distribution of viral antigen in nervous canine distemper.

M Vandevelde, A Zurbriggen, R J Higgins, D Palmer.   

Abstract

Canine distemper virus (CDV) antigen was demonstrated immunocytochemically in the central nervous system (CNS) of 19 dogs killed from 16 to 170 days after infection. In the earliest lesions, infection of glial cells preceded demyelination, and the degree of myelin destruction correlated with the amount of viral antigen in the tissue. It was concluded that initial demyelination in distemper is directly viral-induced, but the nature of the infected glial cells remains uncertain. Ependymal infection and spread of virus in the subependymal white matter was often seen, suggesting invasion of CDV into the CNS along the CSF pathways. Inflammation during the latter stages of the infection appeared to be associated with viral clearance from the CNS in most dogs. In two dogs with chronic progressive neurologic distemper, viral antigen was still present in the brain suggesting that viral persistence and associated immunologic reactions may contribute to further myelin damage. With the exception of one dog that survived for 6 months after infection, viral antigen was no longer detected in the dogs that had recovered.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4050335     DOI: 10.1007/BF00687803

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  17 in total

1.  Observations on viral demyelinating encephalomyelitis. Canine distemper.

Authors:  H Wiśniewski; C S Raine; W J Kay
Journal:  Lab Invest       Date:  1972-05       Impact factor: 5.662

2.  Pathogenesis of canine distemper.

Authors:  M J Appel
Journal:  Am J Vet Res       Date:  1969-07       Impact factor: 1.156

3.  Demyelination in experimental canine distemper virus infection: immunological, pathologic, and immunohistological studies.

Authors:  M Vandevelde; R J Higgins; B Kristensen; F Kristensen; A J Steck; U Kihm
Journal:  Acta Neuropathol       Date:  1982       Impact factor: 17.088

4.  Early events in canine distemper demyelinating encephalomyelitis.

Authors:  B A Summers; H A Greisen; M J Appel
Journal:  Acta Neuropathol       Date:  1979-04-12       Impact factor: 17.088

5.  Myelin-specific autoantibodies associated with central nervous system demyelination in canine distemper virus infection.

Authors:  S Krakowka; B McCullough; A Koestner; R Olsen
Journal:  Infect Immun       Date:  1973-11       Impact factor: 3.441

6.  On the development of CNS lesions in natural canine distemper encephalomyelitis.

Authors:  C S Raine
Journal:  J Neurol Sci       Date:  1976-11       Impact factor: 3.181

7.  Lymphocyte-mediated immune cytotoxicity in dogs infected with virulent canine distemper virus.

Authors:  M J Appel; W R Shek; B A Summers
Journal:  Infect Immun       Date:  1982-08       Impact factor: 3.441

8.  Observations on the distribution of canine distemper virus in the central nervous system of dogs with demyelinating encephalitis.

Authors:  M Vandevelde; B Kristensen
Journal:  Acta Neuropathol       Date:  1977-11-28       Impact factor: 17.088

9.  Immunological and pathological findings in demyelinating encephalitis associated with canine distemper virus infection.

Authors:  M Vandevelde; F Kristensen; B Kristensen; A J Steck; U Kihm
Journal:  Acta Neuropathol       Date:  1982       Impact factor: 17.088

10.  Primary demyelination in experimental canine distemper virus induced encephalomyelitis in gnotobiotic dogs. Sequential immunologic and morphologic findings.

Authors:  R J Higgins; S G Krakowka; A E Metzler; A Koestner
Journal:  Acta Neuropathol       Date:  1982       Impact factor: 17.088

View more
  29 in total

1.  Canine distemper virus uses both the anterograde and the hematogenous pathway for neuroinvasion.

Authors:  Penny A Rudd; Roberto Cattaneo; Veronika von Messling
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

2.  Canine distemper virus-immune complexes induce bystander degeneration of oligodendrocytes.

Authors:  C Botteron; A Zurbriggen; C Griot; M Vandevelde
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

3.  Sequence analysis and expression of the attachment and fusion proteins of canine distemper virus wild-type strain A75/17.

Authors:  P Cherpillod; K Beck; A Zurbriggen; R Wittek
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

4.  Antibody-induced generation of reactive oxygen radicals by brain macrophages in canine distemper encephalitis: a mechanism for bystander demyelination.

Authors:  C Griot; T Bürge; M Vandevelde; E Peterhans
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

5.  Evidence of oligodendrocyte infection and degeneration in canine distemper encephalomyelitis.

Authors:  W F Blakemore; B A Summers; M G Appel
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

6.  The retrospective use of a peroxidase technique for confirmation of suspected canine distemper in Kenya.

Authors:  P K Gathumbi
Journal:  Vet Res Commun       Date:  1993       Impact factor: 2.459

7.  Ultrastructural and biochemical findings in brain cell cultures infected with canine distemper virus.

Authors:  T Glaus; C Griot; A Richard; U Althaus; N Herschkowitz; M Vandevelde
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

8.  Antiviral antibodies stimulate production of reactive oxygen species in cultured canine brain cells infected with canine distemper virus.

Authors:  T Bürge; C Griot; M Vandevelde; E Peterhans
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

9.  Oligodendroglial pathology in canine distemper virus infection in vitro.

Authors:  A Zurbriggen; M Vandevelde; M Dumas; C Griot; E Bollo
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

10.  Herpes-simplex-related antigen in human demyelinative disease and encephalitis.

Authors:  J R Martin; R K Holt; H D Webster
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.